Clinical evaluations and expanded access trials indicate that intranasal foralumab possesses a favorable safety profile with minimal treatment-related adverse events. Reported side effects are generally mild, including occasional localized reactions such as minor temporary tingling or numbness in the lips and tongue. Unlike systemic intravenous monoclonal antibodies, nasal delivery successfully avoids severe systemic immunosuppression, cytokine release syndrome, or broad toxicity, though patients must still be monitored under clinical trial protocols for individual sensitivities.